Clinical Trial Update: A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for KRN23 in subjects with tumor-induced osteomalacia or epidermal nevus syndrome has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermal Nevus Syndrome
• Tumor-induced Osteomalacia

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome | Phase 2 | Status: COMPLETED